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treated with infliximab or intravenous golimumab
lorie a Ellis1  
Elisabetta Malangone-
Monaco2  
helen Varker3  
Diana stetsovsky3  
Maureen Kubacki1  
Raphael J Dehoratius1,4  
Shelly Kafka1
1Real World Value and Evidence, 
Janssen scientific affairs, llC, 
horsham, Pa, Usa; 2life sciences, 
IBM Watson Health, Armonk, NY, 
Usa; 3Life Sciences, IBM Watson 
Health, Cambridge, MA, USA; 4Janssen 
Immunology, Medical Affairs, Sidney 
Kimmel School of Medicine, Thomas 
Jefferson University, Philadelphia, Pa, 
Usa
Purpose: The objectives of this study were to evaluate and compare treatment patterns and 
infusion-related health care resource expenditures for rheumatoid arthritis (RA) patients initiat-
ing golimumab for intravenous use (GLM-IV) and infliximab (IFX) therapy and to assess cost 
implications from the commercial perspective.
Methods: Adult RA patients with a new episode of GLM-IV or IFX treatment between Janu-
ary 1, 2014 and March 31, 2016 were identified from MarketScan databases and evaluated for 
maintenance infusion intervals and related costs of treatment. IFX and GLM-IV patients were 
matched 1:1 on index medication treatment duration, gender, payer type, prior biologic use, 
and post-index methotrexate use. Paid amounts for drugs and associated administration costs 
were applied to treatment group dosing patterns.
Results: Final matched treatment groups included 547 GLM-IV and 547 IFX patients (mean age 
= 55–56 years). Mean (SD) follow-up was 609 (161) days for GLM-IV and 613 (163) days for 
IFX. Treatment duration was 396 (240) days for GLM-IV and 397 (239) days for IFX. Overall, 
80% of GLM-IV and 39% of IFX maintenance infusions were given approximately every 8 
weeks; and 6% of GLM-IV and 53% of IFX maintenance infusions occurred more frequently 
than every 8 weeks (P<0.001). When weighting of the maintenance infusion interval was applied, 
the mean number of induction plus maintenance infusions during the first year of treatment 
was estimated at 7.03 for GLM-IV and 9.48 for IFX. From the commercial perspective, drug 
plus administration costs per infusion were $5,846 for GLM-IV and $5,444 for IFX with total 
annual cost of therapy for GLM-IV patients costing $10,507 less than that for IFX patients in 
the first year and $6,774 less than that for IFX patients in subsequent years.
Conclusion: Annual GLM-IV drug plus administration costs for commercial health plans 
were significantly less than IFX in RA patients due to differences in real-world dosing and 
administration.
Keywords: rheumatoid arthritis, infliximab, golimumab, dosing, treatment patterns
Introduction
Rheumatoid arthritis (RA) is the most common adult chronic inflammatory arthritis 
condition, affecting ~0.5% to 1% of the world population, including an estimated 
1.3–1.8 million Americans.1,2 This autoimmune disease appears to stem from genetic 
susceptibility and environmental triggers in which B-cell and T-cell activation, autoan-
tibody production, tumor necrosis factor alpha (TNF-α), and IL-6 play central roles. 
The characteristic joint synovium inflammation and degenerative articular changes 
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are often accompanied by systemic complications of the 
underlying disease, such as those affecting cardiovascular, 
pulmonary, and gastrointestinal systems; cancers; and psy-
chiatric diseases.1,3 Annual economic costs for RA in the 
USA were estimated at $8.4 billion (2,005 dollars) in direct 
health care expenditures and $10.9 billion in indirect costs 
resulting from the disease and comorbid conditions, along 
with psychosocial effects of the disease and impacts on 
health-related quality of life.4
Treatment guidelines focus on managing inflammation, 
preventing structural damage, controlling pain, and managing 
comorbid conditions with the goal of optimizing patients’ 
participation in activities of daily living by using a treat-to-
target strategy that adjusts therapy to meet treatment goals.5–7 
Early intervention with disease-modifying antirheumatic 
drugs (DMARDs) has become the backbone of the treat-
to-target approach, in which therapy is regularly reassessed 
based on progress toward relieving signs and symptoms 
and minimizing disease activity.3,8 Initial therapy typically 
involves conventional DMARDs, such as methotrexate, 
leflunomide, or sulfasalazine. For patients with moderate 
or high disease activity, the guidelines from the American 
College of Rheumatology recommend use of conventional 
DMARD combinations with or without a biologic targeted 
immune therapy or biologic therapy alone, such as abata-
cept, adalimumab, etanercept, golimumab, and infliximab 
(IFX).9 The most prevalent biologics used for RA are the 
TNF inhibitors (anti-TNF agents); however, US guidelines 
do not provide recommendations for prioritizing between 
agents of the same class, leaving this decision solely in the 
hands of individual providers.2,5,9
Golimumab (GLM) for intravenous use (GLM-IV) and 
IFX are currently the only anti-TNF agents approved in the 
USA for IV administration in treating patients with RA. 
Despite having similar mechanisms of action, there are sig-
nificant differences in dosing and administration recommen-
dations between GLM-IV and IFX. GLM is a fully human 
monoclonal antibody specific for human TNF-α, approved for 
IV administration in July 2013 for moderate-to-severe active 
RA in combination with methotrexate. The 2 mg/kg dose is 
administered by IV infusion over 30 minutes at weeks 0 and 
4 for induction and then as a maintenance regimen every 8 
weeks.10,11 Under this dosing schedule, patients can receive 
seven GLM-IV infusions in their first year of therapy. IFX is 
a chimeric IgG1κ monoclonal antibody specific for human 
TNF-α. The recommended 3 mg/kg dose is given by IV 
infusion over a minimum of 2 hours at weeks 0, 2, and 6 for 
induction, followed by a maintenance regimen every 8 weeks 
in combination with methotrexate. Patients with insufficient 
response may have the dose increased up to 10 mg/kg or may 
have the frequency increased up to every 4 weeks.12 Under 
this dosing schedule, patients can receive between 8 and 14 
IFX infusions in their first year of therapy.
The differences in dosing and administration recommen-
dations, as well as the subtle differences in protein structure 
between GLM-IV and IFX, can affect the use of health care 
resources and costs. However, no studies to date have directly 
compared the dosing and administration regimens and 
associated resource use and costs for these two IV anti-TNF 
RA medications in real-world populations. The comparison 
of these agents is complicated by noted differences in the 
populations treated with each agent since early studies have 
shown that a higher proportion of patients receiving GLM-IV 
tended to be older, with longer-standing active disease and 
had failed more prior biologic therapies compared with the 
population receiving IFX.13,14 Therefore, studies in matched 
patient cohorts are important to ensure that confounding 
factors are controlled in any analysis.
The objectives of this study were to evaluate and com-
pare the treatment patterns and infusion-related health care 
resource expenditures for matched RA patient cohorts initiat-
ing GLM-IV and IFX therapy identified in real-world health 
care claims data sets and to assess cost implications from the 
commercial perspective
Methods
study design
This retrospective, observational cohort study used admin-
istrative health care claims data from a large geographically 
distributed US data source to examine the real-world dosing 
and administration patterns and direct infusion-related health 
care expenditures for matched patients during the first year 
after initiating RA treatment with either GLM-IV or IFX.
Data source
A de-identified US administrative health care claims data-
base for years 2013–2016 was used for this study (Mar-
ketScan® Commercial Claims and Encounters Database 
and Medicare Supplemental and Coordination of Benefit 
Database [Truven Health Analytics, Ann Arbor, MI, USA]). 
The data consist of complete longitudinal records of inpa-
tient services, outpatient services, and prescription drug 
claims for commercially insured and Medicare-eligible 
patients covered under a variety of health plans, including 
dates of service, places of service, and all payments. All 
database records are de-identified and fully compliant with 
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US patient  confidentiality requirements set forth in Sec-
tions 164.514 (a)-(b)1ii of the Health Insurance Portability 
and Accountability Act regarding the determination and 
documentation of statistically de-identified data; therefore, 
Institutional Review Board approval to conduct this study 
was not necessary.
The measurement of study variables was based on 
inpatient medical, outpatient medical, and outpatient phar-
maceutical claims data using ICD, Ninth Revision, Clini-
cal Modification (ICD-9-CM) codes, ICD, Tenth Revision 
(ICD-10) codes, Current Procedural Terminology® (CPT) 
codes, Healthcare Common Procedure Coding System 
(HCPCS) codes, and US National Drug Codes (NDCs), 
as appropriate.
Subject selection
Adult patients (at least 18 years of age on the index date) 
were selected if they had an ICD-CM diagnosis code for 
RA (ICD-9: 714.xx; ICD-10 diagnosis codes: M05, M06) 
in the 12 months before or within 30 days following the first 
medical claim for GLM-IV (HCPCS code J1604) or IFX 
(HCPCS code J1745) during the study identification period 
(January 1, 2014 and March 31, 2016). The study index 
date was defined as the first observed claim for GLM-IV or 
IFX during the study identification period. No evidence of 
prior index medication use in the 12 months prior to index 
was permitted. All patients had continuous medical and 
pharmacy benefit enrollment for at least 12 months before 
index (baseline period) and for at least 12 months following 
the index date (follow-up period). Patients were excluded 
if they had a diagnosis code for pregnancy observed in the 
data at any time.
Patient demographic, clinical, and post-index character-
istics were assessed for the GLM-IV and IFX index cohorts 
to assess the need for matching. Demographic variables 
measured on the index date included age, sex, payer (Com-
mercial or Medicare), health plan type, and geographic 
region of residence (Northeast, North Central, South, West). 
Clinical characteristics found in medical claims over the 
entire 12-month pre-index period included indices for RA 
severity and comorbidity burden. The claims-based index 
for RA severity (CIRAS) uses claims data for a medical 
records-based index of RA severity.15 The Deyo–Charlson 
Comorbidity Index (DCI) is an aggregate measure of comor-
bidity based on weighted values for select diagnoses, which 
was adjusted to eliminate RA from its computation since all 
patients will have that diagnosis.16 The number of unique 
diagnoses is based on counts of the unique diagnoses at the 
3-digit ICD-9-CM and ICD-10 level, and the number of 
unique prescription drugs counts the total number of unique 
NDCs in outpatient prescription claims.17 The presence of 
specific comorbidities of interest included essential hyperten-
sion, disorders of lipid metabolism, respiratory symptoms, 
diabetes mellitus, depression, osteoporosis, interstitial lung 
disease, ischemic heart disease, psoriatic arthritis, and 
psoriasis. Pre-index usage of RA-indicated biologics and 
non-biologic DMARDs, including methotrexate, cortico-
steroids, hydroxychloroquine, leflunomide, sulfasalazine, 
and azathioprine, was summarized from prescription claims.
After assessment of the baseline and follow-up variables, 
patients in the GLM-IV cohort were matched 1:1 with IFX 
patients on the following variables: gender, payer type, prior 
biologic use, index medication treatment duration, and post-
index methotrexate use.
Outcomes
Key outcome variables included dosing and administration, 
treatment patterns, and costs.
Dosing and administration outcomes consisted of the 
number of infusions, the number of vials per infusion of 
the index drug, and the infusion interval for induction and 
maintenance infusions of the index drug. The number of index 
drug infusions was calculated for outpatient medical claims of 
the study drug occurring at the physician’s office, in a clinic, 
or other outpatient facility. Vials of study drug per infusion 
were computed by dividing the paid amount of the drug claim 
by the published wholesale acquisition cost (Analysource) 
for the applicable time period of the paid claim. Infusions 
were designated as either induction or maintenance according 
to the administration schedules in each drug’s prescribing 
information, with the first two GLM-IV infusions and the 
first three IFX infusions identified as induction doses and 
all subsequent doses considered maintenance.12 The infu-
sion interval between administrations was calculated as the 
number of days between claims for a study drug.
Treatment pattern outcomes included index medication 
persistence (treatment duration and proportion of patients 
with an index discontinuation), administration billing time 
and procedures, and concomitant use of methotrexate or 
corticosteroids during index medication use in the follow-
up period. Treatment duration was calculated as the number 
of days from the index date until the date of the last drug 
administration claim in the dataset plus a clinical benefit 
period equal to 56 days. Discontinuation was assessed as the 
proportion of patients who discontinued index medication 
over the follow-up period and as the total index treatment 
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duration. Discontinuation was determined by a switch to a 
non-index biologic or the absence of a claim for the study 
index medication for at least 168 days (three times the clinical 
benefit of 56 days) after the last observed claim. Concomi-
tant usage of methotrexate and/or corticosteroids was based 
on the respective days of supply in outpatient prescription 
claims on or after the index date through the duration of 
index drug therapy.
Drug and infusion costs were computed from total paid 
amounts on adjudicated claims, including health plan payments, 
patient copayments, deductibles, and coinsurance. Inflation was 
adjusted to 2,017 US dollars using the Medical Care component 
of the US Bureau of Labor Statistics Consumer Price Index.18 
Infusion-related costs were obtained for claims on the same 
day as the drug claim with the following CPT codes: first hour 
96365, 96413; additional hour 96366, 96415; IV push 96372, 
96374, 96375; additional sequential infusion 96367. Average 
drug and administration costs per IFX infusion or GLM-IV 
infusion were derived from all observed GLM-IV and IFX 
infusions provided there was a valid cost value. Claims with $0 
cost were excluded. The drug and administration costs of the 
first year following GLM-IV or IFX initiation were computed 
in two ways by multiplying the average drug plus administration 
cost per infusion by a) the expected number of infusions based 
on the approved dosage and administration in the prescribing 
information, and b) the weighted number of infusions in a given 
year from this study’s results. The weighted number of infusions 
per year was computed from the proportion of maintenance 
infusion intervals occurring plus the addition of the indicated 
number of induction intervals.
analysis
Bivariate analyses of all dependent and independent variables 
were summarized descriptively, with categorical variables 
presented as the count and percentage of patients, and con-
tinuous variables providing the number of observations, the 
mean, SD, and median. Statistical tests of significance for 
observed differences between treatment groups were con-
ducted using chi-squared tests for categorical variables and 
t-tests for continuous variables. The threshold of statistical 
significance for all analyses was set a priori at 0.05. All 
analyses were conducted using SAS software, version 9.4 
(SAS Institute Inc, Cary, NC).
Results
Population characteristics
The initial unmatched study samples consisted of 647 GLM-
IV and 881 IFX patients (Figure 1, Table). After matching 
1:1 for gender, payer type, prior biologic use, index medica-
tion treatment duration, and post-index methotrexate use, 
the final study sample consisted of 547 GLM-IV and 547 
IFX patients adequately matched for baseline demographics 
and clinical characteristics and index medication treatment 
duration in the follow-up period (Tables 1–4). The matched 
populations were predominantly female (82%) with mean age 
55–56 years (Table 3). Indices of RA severity and comorbid-
ity burden were not statistically different between matched 
treatment groups (Table 4). Common comorbidities included 
hypertension, disorders of lipid metabolism, respiratory 
symptoms, and diabetes (Table 4). Prior to initiating GLM-
IV or IFX treatment, over half of the patients had treatment 
with methotrexate (55.0% of GLM-IV and 60.0% of IFX 
patients) and 38.2% of all patients had no prior biologic use. 
Pre-index corticosteroid use was found in 47.7% of GLM-IV 
and 44.6% of IFX patients (Table 4).
Post-index treatment patterns
The mean (SD) post-index follow-up was 609 (161) days 
for GLM-IV patients and 613 (163) days for IFX patients 
(Table 3), during which the mean treatment duration was 396 
(240) days for GLM-IV and 397 (239) days for IFX therapy 
(Table 5). Discontinuation occurred for 53.7% of patients in 
both cohorts at a mean of 241 (165) days for GLM-IV and 
244 (171) days for IFX patients.
Post-index concomitant methotrexate use was observed 
in 51.7% of patients in both GLM-IV and IFX treatment 
cohorts for approximately one-third of total treatment days. 
Post-index concomitant corticosteroid use was observed in 
38% and 49% of GLM-IV- and IFX-treated patients, respec-
tively, although use was limited, occurring in only 2.2% and 
3.9% of GLM and IFX treatment days, respectively (Table 5).
Dosing and administration outcomes
A total of 3,961 GLM-IV and 4,716 IFX infusions were 
administered during the study period. GLM-IV patients 
received significantly fewer infusions per patient during 
follow-up compared with IFX patients. The mean (SD) 
number of induction plus maintenance infusions per patient 
observed during follow-up was 7.2 (4.3) for GLM-IV vs 
8.6 (5.6) for IFX (P=0.018, Table 5). Likewise, on average, 
GLM-IV patients in this study required fewer vials per infu-
sion (4.1) than did IFX patients (4.7; Table 5). All GLM-IV 
and IFX infusions were associated with a claim for at least 
1 hour of billed infusion time; however, fewer than 1% of 
GLM-IV infusions vs 96% of IFX infusions had claims for 
more than 1 hour of billed infusion time.
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Figure 1 Subject selection. 
Note: aIndex date is the first GLM-IV or IFX claim after January 1, 2014. bPatients may not have had their index medication within 12 months pre-index; however, they may 
have received the non-index drug during the pre-index period. In addition, patients could have no claims for a second non-study biologic on the index date. 
Abbreviations: GLM-IV, golimumab intravenous; IFX, infliximab; RA, rheumatoid arthritis.
RA diagnosis and claim for GLM-IV or IFX January 2014 through March 2016a
Continuous medical and prescription coverage ≥12 months pre-index
Age ≥18 at index and no evidence of pregnancy pre- or post-index
Continuous medical and prescription coverage ≥12 months post-index
No GLM-IV or IFX claims during 12 months pre-indexb
Final cohorts after matching
GLM-IV 2,349 (100%) IFX 12,612 (100%)
GLM-IV 1,585 (67.5%) IFX 7,336 (58.2%)
GLM-IV 1,555 (66.2%) IFX 7,097 (56.3%)
GLM-IV 681 (29.0%) IFX 4,105 (32.5%)
GLM-IV 647 (27.5%) IFX 881 (7.0%)
GLM-IV 547 (23.3%) IFX 547 (4.3%)
Table 1 Demographic characteristics of patients prior to matching
GLM-IV
N=647
IFX
N=881
P-value
Age, years (mean, SD) 57.3 12.8 55.7 12.3 0.014
Age group (N, %) 0.269
18–34 24 3.7% 41 4.7%
35–44 72 11.1% 113 12.8%
45–54 174 26.9% 221 25.1%
55–64 216 33.4% 319 36.2%
65+ 161 24.9% 187 21.2%
Sex (%, N) 0.017
Male 116 17.9% 202 22.9%
Female 531 82.1% 679 77.1%
Payer (N, %) 0.167
Commercial 475 73.4% 674 76.5%
Medicare 172 26.6% 207 23.5%
Length of follow-up, days (mean, SD) 614 161 627 163 0.122
Total all-cause pre-index health care costs, $ (mean, SD) $44,255 $76,351 $34,027 $37,370 <0.001
Abbreviations: GLM-IV, golimumab intravenous; IFX, infliximab.
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Table 2 Clinical characteristics of patients prior to matching
GLM-IV
N=647
IFX
N=881
P-value
RA and comorbidity indices (mean, SD)
CIRAS 5.81 1.71 5.95 1.89 0.118
DCIa 0.76 1.18 0.71 1.23 0.398
Number of unique diagnosesb 21 11.18 20 11.33 0.406
Number of unique prescription drugs 18 10.50 18 10.62 0.740
Specific comorbid conditions (N, %)
Essential hypertension 296 45.7% 373 42.3% 0.184
Disorders of lipoid metabolism 221 34.2% 285 32.3% 0.458
Respiratory symptoms 204 31.5% 254 28.8% 0.255
Diabetes 120 18.5% 141 16.0% 0.192
Depression 74 11.4% 107 12.1% 0.672
Osteoporosis 74 11.4% 96 10.9% 0.740
Interstitial lung disease 55 8.5% 85 9.6% 0.442
Ischemic heart disease 60 9.3% 83 9.4% 0.922
Psoriatic arthritis 41 6.3% 51 5.8% 0.656
Psoriasis 36 5.6% 38 4.3% 0.260
Pre-index non-biologic DMARD use (N, %)
Methotrexate 340 52.6% 536 60.8% 0.001
Corticosteroids 316 48.8% 362 41.1% 0.003
Pre-index biologic use (N, %)      
No biologics 210 32.5% 513 58.2% <0.001
Infliximab 137 21.2% 0 0.0% <0.001
Abatacept 104 16.1% 62 7.0% <0.001
Tocilizumab 83 12.8% 43 4.9% <0.001
Adalimumab 64 9.9% 163 18.5% <0.001
Etanercept 57 8.8% 139 15.8% <0.001
Tofacitinib 31 4.8% 23 2.6% 0.023
Certolizumab pegot 40 6.2% 32 3.6% 0.020
Golimumab subcutaneous 22 3.4% 12 1.4% 0.008
Rituximab 18 2.8% 16 1.8% 0.206
Note: aCalculations to determine DCI excludes rheumatologic disease. bNumber of unique diagnoses was the number of unique three-digit ICD-9-CM codes found pre-index.
Abbreviations: CIRAS, claims-based index for RA severity; DCI, Deyo–Charlson Comorbidity Index; DMARD, disease-modifying antirheumatic drug; GLM-IV, golimumab 
intravenous; ICD-9-CM, ICD Ninth Revision, Clinical Modification; IFX, infliximab; RA, rheumatoid arthritis.
Table 3 Demographic characteristics of matched patients
GLM-IV
N=547
IFX
N=547
P-value
Age, years (mean, SD) 56.3 12.3 55.1 12.4 0.119
Age group (N, %) 0.601
18–34 22 4.0% 29 5.3%
35–44 60 11.0% 68 12.4%
45–54 160 29.3% 143 26.1%
55–64 196 35.8% 204 37.3%
65+ 109 19.9% 103 18.8%
Sex (%, N) 1.000
Male 97 17.7% 97 17.7%
Female 450 82.3% 450 82.3%
Payer (N, %) 1.000
Commercial 431 78.8% 431 78.8%
Medicare 116 21.2% 116 21.2%
Length of follow-up, days (mean, SD) 609 161 613 163 0.688
Total all-cause pre-index health care costs, $ (mean, SD) $43,118 $80,018 $38,396 $38,945 0.215
Abbreviations: GLM-IV, golimumab intravenous; IFX, infliximab.
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The proportion of maintenance infusions administered 
approximately every 8 weeks (>7 weeks and ≤9 weeks) was 
80.2% for GLM-IV vs 38.6% for IFX (P<0.001, Figure 2). 
The proportion of infusions that occurred more frequently 
than every 8 weeks was 5.9% for GLM-IV infusions com-
pared to 52.8% for IFX infusions (P<0.001, Table 5). The 
proportion of infusion intervals exceeding 9 weeks was 
13.9% for GLM-IV and 8.6% for IFX with the average infu-
sion interval in this category being 12 weeks.
When weighting of the maintenance infusion interval 
was applied, the annual number of maintenance infusions 
was estimated as 5.05 for GLM-IV and 6.48 for IFX infu-
sions and the number of total induction plus maintenance 
infusions per the first year of therapy was estimated at 7.03 
for GLM-IV and 9.48 for IFX.
Total mean drug cost per infusion for commercially 
insured patients receiving GLM-IV therapy was $5,622 
Table 4 Clinical characteristics of matched patients
GLM-IV
N=547
IFX
N=547
P-value
RA and comorbidity indices (mean, SD)
CIRAS 5.93 1.69 6.06 1.78 0.213
DCIa 0.73 1.15 0.71 1.29 0.824
Number of unique diagnosesb 20 10.74 21 11.30 0.337
Number of unique prescription drugs 18 10.47 20 10.41 0.017
Specific comorbid conditions (N, %)
Essential hypertension 240 43.9% 236 43.1% 0.807
Disorders of lipoid metabolism 176 32.2% 178 32.5% 0.897
Respiratory symptoms 171 31.3% 161 29.4% 0.511
Diabetes 100 18.3% 84 15.4% 0.196
Depression 62 11.3% 69 12.6% 0.514
Osteoporosis 60 11.0% 53 9.7% 0.487
Interstitial lung disease 49 9.0% 45 8.2% 0.666
Ischemic heart disease 47 8.6% 46 8.4% 0.914
Psoriatic arthritis 34 6.2% 35 6.4% 0.901
Psoriasis 27 4.9% 27 4.9% 1.000
Pre-index non-biologic DMARD use (N, %)
Methotrexate 301 55.0% 328 60.0% 0.099
Corticosteroids 261 47.7% 244 44.6% 0.303
Pre-index biologic use (N, %)
No biologics 209 38.2% 209 38.2% 1.000
Infliximab 106 19.4% 0 0.0% <0.001
Abatacept 74 13.5% 55 10.1% 0.024
Tocilizumab 63 11.5% 37 6.8% <0.001
Adalimumab 57 10.4% 143 26.1% <0.001
Etanercept 44 8.0% 134 24.5% <0.001
Tofacitinib 29 5.3% 22 4.0% 0.315
Certolizumab pegot 26 4.8% 30 5.5% 0.583
Golimumab subcutaneous 15 2.7% 11 2.0% 0.427
Rituximab 10 1.8% 14 2.6% 0.409
Note: aCalculations to determine DCI excludes rheumatologic disease. bNumber of unique diagnoses was the number of unique three-digit ICD-9-CM codes found pre-index.
Abbreviations: CIRAS, claims-based index for RA severity; DCI, Deyo–Charlson Comorbidity Index; DMARD, disease-modifying antirheumatic drug; GLM-IV, golimumab 
intravenous; ICD-9-CM, ICD Ninth Revision, Clinical Modification; IFX, infliximab; RA, rheumatoid arthritis.
($3,641) and $5,083 ($4,339) for IFX (Table 6). Mean 
administration cost per infusion for commercially insured 
GLM-IV infusions was $224 ($151) and $360 ($281) for 
IFX infusions.
Estimation of annual cost of therapy from 
the commercial perspective
The annual drug plus administration costs for the first year of 
GLM-IV therapy was estimated based on the recommended 
dosing in the GLM-IV and IFX prescribing information. 
Based on a total of seven infusions in the first year (two 
induction infusions occurring at weeks 0 and 4 and five main-
tenance infusions occurring at an infusion interval of every 
8 weeks) and the commercial cost per infusion (Table 6), the 
expected GLM-IV drug plus administration cost in the first 
year was estimated at $40,922 (Figure 3). Based on a total 
of eight infusions for IFX recommended in the prescribing 
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information (three induction infusions occurring at weeks 0, 
2, and 6 and five maintenance infusions occurring at an infu-
sion interval of every 8 weeks), and the commercial cost per 
infusion (Table 6), the expected IFX drug plus administration 
cost in the first year was estimated at $43,552 (Figure 3).
When real-world dosing and administration data, 
weighted maintenance infusion intervals, and commercial 
costs were used, the first year of GLM-IV therapy (7.03 
infusions/year) was estimated at $41,104 while IFX therapy 
(9.48 infusions/year) was estimated at $51,611 in the first 
year of therapy (Figure 3).
Discussion
This study, conducted on a large database population of 
US self-insured RA patients from diverse practice settings 
across the USA, found significant differences in treatment 
patterns between GLM-IV and IFX-treated patients; notably 
a significantly greater proportion of GLM-IV maintenance 
infusions were provided every 8 weeks with reduction of 
billed administration time that resulted in lower annual treat-
ment cost per patient for commercial insurers. Taken together, 
these findings suggest that GLM-IV provides a more efficient 
treatment option for infused anti-TNF therapy.
Table 5 Treatment patterns and infusion patterns
GLM-IV
N=547
IFX
N=547
P-value
Days from last pre-index biologic dose to index date (mean, SD) 68.6 42.3 70.6 41.3 0.424
Duration of index therapy, days (mean, SD) 396 240 397 239 0.928
Patients who discontinued or switched (N, %) 294 53.7% 294 53.7% 1.000
Discontinued index medication (N, %) 119 21.8% 162 29.6% 0.003
Switched to a different biologic (N, %) 175 32.0% 132 24.1% 0.004
Days to discontinuation or switch (mean, SD) 241 165 244 171 0.799
Concomitant methotrexate use (N, %) 283 51.7% 283 51.7% 1.000
Days of concomitant methotrexate (mean, SD) 34.7% 39.4% 35.0% 40.4% 0.892
Concomitant corticosteroid use (N, %) 210 38.4% 268 49.0% <0.001
Days of concomitant corticosteroids (mean, SD) 2.2% 4.3% 3.9% 6.6% <0.001
Total number of index drug infusions 3,961 4,716
Number of infusions per patient (mean, SD) 7.2 4.3 8.6 5.6 0.018
1 (N, %) 30 5.5% 42 7.7%  
2 (N, %) 57 10.4% 45 8.2%  
3 (N, %) 54 9.9% 30 5.5%  
4 (N, %) 50 9.1% 44 8.0%  
5+ (N, %) 356 65.1% 386 70.6%  
Vials per infusiona (mean, SD) 4.1 2.6 4.7 4.0 <0.001
Induction intervalsb,c (N, %) <0.001
£2 weeks 2 0.4% 296 30.7%  
>2 weeks £3 weeks 4 0.8% 111 11.5%  
>3 weeks £4 weeks 270 52.2% 259 26.8%  
>4 weeks £5 weeks 127 24.6% 104 10.8%  
>5 weeks £7 weeks 30 5.8% 94 9.7%  
>7 weeks £9 weeks 55 10.6% 58 6.0%  
>9 weeks 29 5.6% 43 4.5%  
Maintenance intervalsb,c (N, %) <0.001
£4 weeks 55 1.9% 330 10.3%  
>4 weeks £5 weeks 16 0.6% 228 7.1%  
>5 weeks £7 weeks 100 3.5% 1,135 35.4%  
>7 weeks £9 weeks 2,322 80.2% 1,237 38.6%  
>9 weeksd 404 13.9% 274 8.6%  
Interval durations, all intervals, days (mean, SD) 54.1 13.9 44.3 32.4 <0.001
Maintenance interval durations, days (mean, SD) 59.6 14.8 49.4 17.0 <0.001
Note: aVials per infusions were computed by dividing the amount paid by the wholesale acquisition cost. bCount represents infusion intervals, not the number of infusions. 
For example, a patient with three infusions will have two infusion intervals. cGLM-IV maintenance starts with the third dose, so dose interval two-to-three is the first GLM-IV 
maintenance interval. IFX maintenance starts with the fourth dose, so dose interval three-to-four is the first IFX maintenance interval. dWhen maintenance infusion intervals 
exceeded 9 weeks, the average infusion interval was ~12 weeks for both IFX and GLM-IV cohorts.
Abbreviations: GLM-IV, golimumab intravenous; IFX, infliximab.
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Consideration of efficiency in the delivery of health care 
is growing in importance. The Institute of Medicine (IOM) 
has defined high quality of care as consisting of six impor-
tant domains: safe, effective, timely, efficient, equitable, and 
patient-centered.19,20 Phase III studies of IFX and GLM-IV 
have demonstrated the safety and effectiveness, two of the 
six domains of high-quality health care, of both agents in 
patients with RA. Head-to-head studies of these agents have 
not been conducted to differentiate the clinical or safety 
profiles of these agents in RA patients, although differences 
in the protein structures of these agents could translate into 
differences in tolerability among patients treated with fully 
human vs chimeric murine/human proteins. To address this 
possibility, a real-world pragmatic trial is underway to assess 
whether the higher occurrence of infusion reactions for IFX 
Figure 2 Distribution of maintenance infusions. 
Notes: aAll differences between cohorts for the proportions of maintenance infusions are significant at P<0.001. When maintenance infusion intervals exceeded 9 weeks, the 
average infusion interval was ~12 weeks for both IFX and GLM-IV cohorts. 
Abbreviations: GLM-IV, golimumab intravenous; IFX, infliximab.
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Table 6 Drug and infusion expenditures
GLM-IV
N=547
IFX
N=547
Drug costs per infusiona
Commercial (N) 3,090 3,700
Paid amount, $ (mean, SD) $5,622 $3,641 $5,083 $4,339
Infusion costs per infusiona
All infusions with non-drug costs (N) 3,746 4,487
Commercial
Infusions with non-drug costs (N) 2,964 3,568
Paid amount, $ (mean, SD) $224 $151 $360 $281
Note: aExcludes claims with zero dollar costs.
Abbreviations: GLM-IV, golimumab intravenous; IFX, infliximab.
than for GLM noted in Phase III trials is observed in the 
real-world setting.21
The findings from the present study, however, suggest 
that under the IOM framework, GLM-IV may achieve higher 
quality than IFX through impacting domains of timeliness 
and efficiency. Timeliness, as defined by Agency for Health 
care Research and Quality (AHRQ), is care that reduces wait 
times and harmful delays for both those who receive and 
those who give care.20 In this study, GLM-IV reduced billed 
infusion time for RA patients significantly compared with 
IFX. Logically, this reduction in billed administration time 
should be derived from reduced time in the clinic for patients, 
and possibly from fewer demands on infusion monitoring 
by staff. A recent time and motion study showed that nearly 
three GLM-IV patients could be treated in the same time 
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required for one IFX infusion and that both patients and staff 
were more satisfied with the shorter in-clinic time associated 
with GLM-IV.22 Efficiency is defined by AHRQ as care that 
avoids waste, including waste of equipment, supplies, ideas, 
and energy. Under this construct, GLM-IV was associated 
with the expected number of infusions per year and fewer 
vials per infusion than IFX while nearly half of IFX infusions 
occurred more frequently than every 8 weeks. Taken together, 
these differences were estimated to equate to nearly $10,500 
per patient per year reduction in commercial payer costs.
The differences in real-world infusion patterns also impact 
other domains of health care quality, including providing 
patient-centered care. Fewer number of infusions and shorter 
infusion times may be important for patients who prefer an 
infusion but have greater life demands related to work or fam-
ily. In this study, patients treated with GLM-IV required fewer 
infusion visits with each visit requiring less time as shown by 
billing records than that observed for IFX patients. Likewise, a 
more predictable, shorter infusion may translate into a greater 
patient capacity for physician offices, which are known to be 
the least costly sites of care for biologic infusion.14
Finally, this study demonstrated that efficiency and pre-
dictable dosing of GLM-IV could translate into cost savings, 
at least by the commercial payer over IFX. We were unable 
to assess whether treatment patterns of GLM-IV differed 
from those of biosimilar IFX because it was not present in 
the dataset during the time of this study. However, given the 
assumption that biosimilar IFX would likely demonstrate 
similar dosing and administration patterns to originator IFX, 
we were able to confirm that GLM-IV treatment patterns 
observed in this study would be cost saving over biosimilar 
IFX under commercial reimbursement scenarios. Further 
real-world studies will be needed to confirm these findings 
and further investigate how infused anti-TNF agents perform 
on various domains of health care quality and cost.
limitations
Use of administrative health care claims, which were intended to 
support reimbursement, may impose limits on the data available 
for analyzing therapies and their outcomes. Misclassifications 
or errors affecting covariates and study outcomes resulting 
from data coding limitations, data entry error, and missing or 
inaccurate codes are possible when relying on administrative 
claims. Medication dosing and treatment patterns were based 
on data from medical and prescription claims in the absence 
of patient charts or physician attestations. It was, therefore, not 
possible to ascertain reasons for deviations from recommended 
dosing or confirm how patients actually took or reacted to 
their medications. Patients’ medical and prescription history 
was limited to health care claims during the reporting years in 
this study, such that patients’ other comorbidities, pharmaco-
therapy, or sociodemographic factors affecting the outcomes 
were unavailable. In addition, disease severity is not directly 
reported in claims data and must be inferred from claims-based 
scores, such as CIRAS and DCI along with prior use of biolog-
ics and post-index use of methotrexate. This analysis focused 
Figure 3 First-year costs of GLM-IV and IFX therapy comparing recommended dosing intervals and real-world dosing intervals in commercially insured patients. 
Abbreviations: GLM-IV, golimumab intravenous; IFX, infliximab.
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on RA patient populations found in MarketScan commercial 
and Medicare databases that are representative of US payers 
and reimbursed paid costs in the time frame studied. Findings 
should not be interpreted outside of RA-labeled indications and 
may not be generalizable to other US or international patient 
populations or reflective of current treatment cost dynamics.
Conclusion
Patients treated with GLM-IV therapy had more consistent 
dosing patterns than IFX-treated patients; this resulted in sig-
nificantly lower drug plus administration costs for commer-
cially insured RA patients than IFX in the first year of care. 
These findings have important implications for population 
health decision makers in understanding health care quality, 
variations in health care utilization, or cost-saving measures.
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